Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma

Naonori Kawakubo, Sakura Tanaka, Yoshiaki Kinoshita, Tatsuro Tajiri, Yoshikazu Yonemitsu, Tomoaki Taguchi

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Purpose: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma. However, what kind of effector cells for the combined therapy were used to show the antitumor effect was unclear. In this study, we performed radiation and rSeV/DC therapy in vivo and examined the effector cells involved. Methods: Dendritic cells were cultured from bone marrow cells, activated with SeV and administered intratumorally at 106 weekly for 3 weeks. Radiation was administered at 4 Gy/time × 3 times. During the treatment, CD4 + and CD8 + cells and natural killer (NK) cells were removed by antibodies. Results: Complete remission of neuroblastoma was observed in 62.5% of individuals in the combined therapy group. By depleting the effector cells using antibodies, the tumor increased in size from an early stage of treatment in the CD4 + and NK cell-depleted group. In contrast, the tumor increased in size in the late stage of treatment in the CD8 + cell-depleted group. Conclusion: The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment. Level of Evidence: V.

元の言語英語
ページ(範囲)1615-1620
ページ数6
ジャーナルJournal of Pediatric Surgery
53
発行部数8
DOI
出版物ステータス出版済み - 8 2018

Fingerprint

Virus Activation
Neuroblastoma
Dendritic Cells
Radiation
Natural Killer Cells
Therapeutics
Neoplasm Antibodies
Sendai virus
Group Psychotherapy
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Antibodies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pediatrics, Perinatology, and Child Health

これを引用

Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma. / Kawakubo, Naonori; Tanaka, Sakura; Kinoshita, Yoshiaki; Tajiri, Tatsuro; Yonemitsu, Yoshikazu; Taguchi, Tomoaki.

:: Journal of Pediatric Surgery, 巻 53, 番号 8, 08.2018, p. 1615-1620.

研究成果: ジャーナルへの寄稿記事

@article{9b002bc3675446febbca4f4b6080d15d,
title = "Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma",
abstract = "Purpose: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma. However, what kind of effector cells for the combined therapy were used to show the antitumor effect was unclear. In this study, we performed radiation and rSeV/DC therapy in vivo and examined the effector cells involved. Methods: Dendritic cells were cultured from bone marrow cells, activated with SeV and administered intratumorally at 106 weekly for 3 weeks. Radiation was administered at 4 Gy/time × 3 times. During the treatment, CD4 + and CD8 + cells and natural killer (NK) cells were removed by antibodies. Results: Complete remission of neuroblastoma was observed in 62.5{\%} of individuals in the combined therapy group. By depleting the effector cells using antibodies, the tumor increased in size from an early stage of treatment in the CD4 + and NK cell-depleted group. In contrast, the tumor increased in size in the late stage of treatment in the CD8 + cell-depleted group. Conclusion: The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment. Level of Evidence: V.",
author = "Naonori Kawakubo and Sakura Tanaka and Yoshiaki Kinoshita and Tatsuro Tajiri and Yoshikazu Yonemitsu and Tomoaki Taguchi",
year = "2018",
month = "8",
doi = "10.1016/j.jpedsurg.2017.08.019",
language = "English",
volume = "53",
pages = "1615--1620",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma

AU - Kawakubo, Naonori

AU - Tanaka, Sakura

AU - Kinoshita, Yoshiaki

AU - Tajiri, Tatsuro

AU - Yonemitsu, Yoshikazu

AU - Taguchi, Tomoaki

PY - 2018/8

Y1 - 2018/8

N2 - Purpose: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma. However, what kind of effector cells for the combined therapy were used to show the antitumor effect was unclear. In this study, we performed radiation and rSeV/DC therapy in vivo and examined the effector cells involved. Methods: Dendritic cells were cultured from bone marrow cells, activated with SeV and administered intratumorally at 106 weekly for 3 weeks. Radiation was administered at 4 Gy/time × 3 times. During the treatment, CD4 + and CD8 + cells and natural killer (NK) cells were removed by antibodies. Results: Complete remission of neuroblastoma was observed in 62.5% of individuals in the combined therapy group. By depleting the effector cells using antibodies, the tumor increased in size from an early stage of treatment in the CD4 + and NK cell-depleted group. In contrast, the tumor increased in size in the late stage of treatment in the CD8 + cell-depleted group. Conclusion: The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment. Level of Evidence: V.

AB - Purpose: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma. However, what kind of effector cells for the combined therapy were used to show the antitumor effect was unclear. In this study, we performed radiation and rSeV/DC therapy in vivo and examined the effector cells involved. Methods: Dendritic cells were cultured from bone marrow cells, activated with SeV and administered intratumorally at 106 weekly for 3 weeks. Radiation was administered at 4 Gy/time × 3 times. During the treatment, CD4 + and CD8 + cells and natural killer (NK) cells were removed by antibodies. Results: Complete remission of neuroblastoma was observed in 62.5% of individuals in the combined therapy group. By depleting the effector cells using antibodies, the tumor increased in size from an early stage of treatment in the CD4 + and NK cell-depleted group. In contrast, the tumor increased in size in the late stage of treatment in the CD8 + cell-depleted group. Conclusion: The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment. Level of Evidence: V.

UR - http://www.scopus.com/inward/record.url?scp=85029590059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029590059&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2017.08.019

DO - 10.1016/j.jpedsurg.2017.08.019

M3 - Article

C2 - 28941928

AN - SCOPUS:85029590059

VL - 53

SP - 1615

EP - 1620

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 8

ER -